

08/30/99
jc674 U.S. PTO

PATENT

ASSISTANT COMMISSIONER FOR PATENTS
Washington, D.C. 20231

Date: August 30, 1999
File No.: 76891

Sir:

Transmitted herewith for filing is the patent application of:

Inventor(s): Jeffrey L.C. Wright

For: **A NUTRITIONAL SUPPLEMENT FOR
LOWERING SERUM TRIGLYCERIDE AND
CHOLESTEROL LEVELS**

Enclosed are:

- (X) 20 pages of specification, including 29 claims and an abstract.
- () an executed oath or declaration, with power of attorney.
- (X) an unexecuted oath or declaration, with power of attorney.
- () sheet(s) of informal drawing(s).
- () sheet(s) of formal drawing(s).
- () Assignment(s) of the invention to _____
- () Assignment Form Cover Sheet.
- () Associate power of attorney.

I hereby certify that this paper is being deposited with the United States Postal Service as Express Mail in an envelope addressed to: Box PATENT APPLICATION / Assistant Commissioner for Patents / Washington DC 20231 on this date.

August 30, 1999 EL215072432US
(date) Express Mail Label No.
V. Hughes
Vickie Hughes

jc674 U.S. PTO
09/30/99

Fee Calculation For Claims As Filed

- | | | | | | | | | |
|------------------------------|-----------|---|----|---|----------|---|------------|-----------|
| a) Basic Fee | | | | | | | | \$ 760.00 |
| b) Independent Claims | <u>3</u> | - | 3 | = | <u>0</u> | x | \$ 78.00 = | \$ _____ |
| c) Total Claims | <u>29</u> | - | 20 | = | <u>9</u> | x | \$ 18.00 = | \$ _____ |
| d) Multiple Dependent Claims | | | | | | | \$260.00 = | \$ _____ |
- () Statement(s) of Status as Small Entity, reducing Filing Fee by half to \$ _____
 - () A check in the amount of \$.00 to cover the filing fee is enclosed.
 - () Charge \$ to Deposit Account No. *****.
 - () Other
 - () The Commissioner is hereby authorized to charge any additional fees which may be required to this application under 37 C.F.R. §§1.16-1.17, or credit any overpayment, to Deposit Account No. *****.
- Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. *****.

120 South Riverside Plaza
22nd Floor
Chicago, Illinois 60606-3903
Telephone: (312) 655-1500

WELSH & KATZ, LTD.

By Gerald T. Shekleton
Gerald T. Shekleton
Registration No. 27,466

A Nutritional Supplement For Lowering Serum Triglyceride and Cholesterol Levels

Field of the Invention

5 The invention relates to control of cholesterol and triglyceride levels in mammals, particularly humans.

Background of the Invention

10 Serum cholesterol and serum triglyceride levels are important factors in the development of cardiovascular disease. In many clinical studies there is a positive correlation between plasma triglycerides and the incidence of cardiovascular disease [1]. Elevated plasma triglyceride level is frequently associated with other atherogenic factors including elevated
15 low-density lipoprotein (LDL)-cholesterol, reduced high-density lipoprotein (HDL)-cholesterol, and small LDL particles [2, 3]. There is growing acceptance that triglycerides act in a synergistic fashion with these other lipid risk factors to increase the incidence of cardiovascular disease [4, 5].
20 Hypertriglyceridemia usually occurs because of insulin resistance, which leads to overproduction of very low-density lipoproteins (VLDL) by the liver [3]. Treatment involves lifestyle changes to decrease body weight and to increase physical activity, both of which improve insulin sensitivity.
25 Drug therapy to lower triglycerides involves the use of fibrates or nicotinic acid [6].

 A number of clinical studies convincingly establish plasma cholesterol and LDL-cholesterol as independent risk factors for coronary heart disease [7]. Pharmacological agents,
30 called statins, lower total plasma cholesterol by inhibiting the synthesis of cholesterol by the liver. The statins reduce the morbidity and mortality rate from cardiovascular disease in high risk, hypercholesterolemic patients [8, 9], but also in persons who exhibit "average" cholesterol levels [10]. Another approach

is to interfere with the intestinal absorption of cholesterol. Certain phytosterols (plant sterols) such as stigmasterol and β -sitosterol lower serum cholesterol act by inhibiting absorption of both dietary and biliary cholesterol from the small intestine [11].

With respect to the most appropriate form of phytosterols for lowering serum cholesterol, some reports indicate that free phytosterols reduce serum cholesterol in animals and humans [12, 13]. However, there is also evidence to indicate that a sterol esterified with a fatty acid may be more effective [14]. Trials show that phytosterol esters of plant fatty acids obtained from canola oil, when incorporated into food such as margarine or mayonnaise, lower total cholesterol and LDL-cholesterol levels by about 10 and 15 percent, respectively [15, 16]. United States Patent No. 5,502,045 (Miettinen et al., issued March 26, 1996) discloses the use of sitostanol esters of canola oil to lower serum cholesterol. BenecolTM (Raisio Benecol Ltd., Raisio, Finland), a margarine that contains such compounds, is now on the market.

The mechanism by which phytosterols or phytosterol esters inhibit absorption of dietary cholesterol by the digestive tract is not fully understood but may involve competitive inhibition of cholesterol uptake from the intestinal lumen or inhibition of cholesterol esterification in the intestinal mucosa [12]. It is known that phytosterols themselves are only poorly absorbed. Vanhanen et al. [17] report that phytosterol esters may also be poorly absorbed by the intestinal tract based on postprandial measurements of β -sitostanol in plasma. A direct measure of phytosterol ester uptake by the digestive tract has not been reported.

When phytosterols are esterified with fatty acids from plant sources such as canola, the long-chain polyunsaturated fatty acids (LCPUFAs) that are incorporated are predominantly of the omega-6 series. Omega-6 fatty acids do not affect plasma

triglycerides. Research to date on fatty acid esters of sterols has focused only on the efficacy of the sterol in lowering cholesterol.

5 Summary of the Invention

The present invention provides a nutritional supplement comprising a sterol and an omega-3 fatty acid, or an ester thereof, for lowering cholesterol and triglyceride levels in the bloodstream of a subject.

10 The present invention also provides a method of lowering cholesterol and triglyceride levels in the bloodstream of a subject, the method including the step of administration of an effective amount of a nutritional supplement comprising a sterol and an omega-3 fatty acid, or an ester thereof, to a
15 subject.

The present invention also provides the use of the nutritional supplement defined herein for lowering cholesterol and triglyceride levels in the bloodstream of a subject.

The present invention further provides a foodstuff
20 composition comprising the nutritional supplement defined herein and a foodstuff, the nutritional value of the foodstuff being enhanced by incorporation of the nutritional supplement defined herein.

The present invention further provides the use of the
25 nutritional supplement defined herein in the manufacture of a foodstuff composition.

The subject is preferably a mammal, more preferably a human.

Sterols are not very soluble in lipid, which
30 complicates their use in lipid-based foods. A mixture of a sterol and a free omega-3 fatty acid, which typically forms a paste at a molar ratio of 1:1, may be used. If a mixture is used, the omega-3 fatty acid can be a free acid or can be in ester form, preferably a succinimidyl, triglyceride,


(C₃-C₁₂)cycloalkyl or (C₁-C₈)alkyl ester, more preferably an ethyl ester. In the mixture, the molar ratio range of omega-3 fatty acid, or an ester thereof, to sterol should be about 0.5 to 8 , preferably 0.76 to 6.4, more preferably 1 to 2.

5 Preferably, the sterol and the omega-3 fatty acid are together in the form of an ester. The sterol esters of the present invention are highly fat-soluble and represent a bifunctional species, since they lower both serum cholesterol and serum triglyceride levels in the bloodstream.

10

Detailed Description of the Preferred Embodiments

The sterols used to prepare the nutritional supplement of the present invention are preferably phytosterols, and preferably have a perhydrocyclopentanophenanthrene ring system
15 as shown below in the compound of formula I:






20

wherein the dashed line is a single or double bond and R is a
25 (C₁-C₁₀)alkyl, substituted (C₁-C₁₀)alkyl, (C₂-C₁₀)alkenyl or substituted (C₂-C₁₀)alkenyl group.

In the present application, the term "sterols" includes sterols in reduced form (stanols), preferably β -sitostanol or fucostanol (reduced fucosterol).

30 One or more sterols can be used to prepare the nutritional supplement. The term "phytosterols" includes sterols from terrestrial or marine plants, seaweed, microalgae, etc. Preferably, the sterol is stigmasterol, sitosterol or fucosterol, as shown below, or β -sitostanol or fucostanol




Fucoesterol is abundant in brown algae. Prior to esterification with the omega-3 fatty acid, fucoesterol can be reduced to fucostanol. Preferably, the reduction is carried out using hydrogen gas in the presence of a suitable catalyst such as palladium on charcoal (Pd/C), but other reduction processes that ultimately yield a food-quality ester, after purification if necessary, may be used.

The nutritional supplement of the present invention comprises one or more omega-3 fatty acids, and is preferably an ester of an acid of the formula:



wherein R¹ is a (C₃-C₄₀) alkenyl group comprising at least one double bond, more preferably 2 to 5 double bonds. More preferably, the omega-3 fatty acid is stearidonic acid 18:4ω3 (SA), eicosapentaenoic acid 20:5ω3 (EPA) or docosahexaenoic acid 22:6ω3 (DHA).



Omega-3 fatty acids, such as EPA and DHA, are long-chain polyunsaturated fatty acids (LCPUFAs) that are abundant in oily fish such as menhaden, salmon, tuna, and sardine, as well as in certain plants and microbes, such as particular fungi and microalgae. The preferred source of omega-3 fatty acids for the present invention is fish oil, more preferably a highly refined fish oil concentrate having approximately 65% omega-3 fatty acid content which is

predominantly EPA and DHA in the form of triglyceride esters. These triglycerides are preferably converted to lower alkyl esters by known methods and used in an esterification with a sterol to form esters, which can be further purified if
5 necessary, for use as nutritional supplements.

The cardiovascular effects of dietary fish oils have long been recognized [18, 19]. Omega-3 fatty acids lower plasma triglyceride concentrations principally by inhibiting synthesis of triacylglycerol and VLDL by the liver [20]. In addition,
10 omega-3 fatty acids are anti-thrombotic and are protective against cardiac arrhythmias [21]. The benefits of fish oil consumption are illustrated by the finding of the Diet and Reinfarction Trial (DART) which showed a reduction of 29% in the overall mortality in survivors of a first myocardial infarction
15 who consumed fish rich in omega-3 fatty acids at least twice weekly [22]. Two recent studies demonstrate the efficacy of omega-3 fatty acid supplementation. In a randomized, double-blind, placebo-controlled trial patients with coronary artery disease who ingested a 1.5g/day fish oil supplement (55%
20 EPA and DHA) for two years had less progression and more regression of their disease based on coronary angiography compared to patients ingesting the placebo [23]. In the GISSI-Prevenzione trial, omega-3 fatty acid supplements in patients who had myocardial infarction reduced cardiovascular death by
25 30% [24]. Although omega-3 fatty acids are anti-atherogenic, they do not lower plasma cholesterol and in some incidences may slightly increase LDL-cholesterol [25]. Safety and toxicological studies spanning several years have shown that fish oils are safe to consume. Recently, fatty acids such as
30 the omega-3 fatty acids from fish oil were granted GRAS (Generally Regarded As Safe) status in the United States, which permits their addition to foods low in long-chain polyunsaturated fatty acids. The typical North American diet contains about 0.15 grams omega-3 fatty acids whereas Inuit may

ingest up to 10 grams of omega-3 fatty acids daily. A daily intake of 2 to 3 grams of omega-3 fatty acids has consistently been shown to lower plasma triglycerides [18]. Therefore, a suitable daily intake of omega-3 fatty acid in the present invention is about 0.1 to about 10 grams, preferably about 2 to about 3 grams, but clearly greater amounts can be tolerated, and may be beneficial.

Phytosterols are considered safe for human consumption. A typical daily intake in North America is about 100 to 300 milligrams. However, a dose of greater than 3 grams of the phytosterol esters are required to have significant impact on plasma cholesterol levels [13]. Such doses are safe with no known side effects. In the present invention, a preferred daily intake of phytosterol is about 2 to about 3 grams.

Phytosterol esters prepared using fish oil as the source of omega-3 fatty acids contain a significant amount of EPA and DHA. Such esters can simultaneously reduce serum cholesterol and serum triglyceride levels. The triglyceride-lowering ability of the omega-3 fatty acid component of the ester is dependent on its entry into the circulatory system. A lipid esterase in the intestinal lumen may be responsible for release of the omega-3 fatty acid from the phytosterol, which would make both species available for uptake into the circulatory system. There is a non-specific lipid esterase, secreted into the intestinal lumen during digestion that is active against a variety of molecular species including cholesterol esters, monoglycerides, and esters of vitamin A [26].

At least one additive, such as listed below, can be included for consumption with the nutritional supplement of the invention and may have, for example, antioxidant, dispersant, antimicrobial, or solubilizing properties. A suitable antioxidant is, for example, vitamin C, vitamin E or rosemary

extract. A suitable dispersant is, for example, lecithin, an alkyl polyglycoside, polysorbate 80 or sodium lauryl sulfate. A suitable antimicrobial is, for example, sodium sulfite or sodium benzoate. A suitable solubilizing agent is, for example, a vegetable oil such as sunflower oil, coconut oil, and the like, or mono-, di- or tri-glycerides.

Additives include vitamins such as vitamin A (retinol, retinyl palmitate or retinol acetate), vitamin B1 (thiamin, thiamin hydrochloride or thiamin mononitrate), vitamin B2 (riboflavin), vitamin B3 (niacin, nicotinic acid or niacinamide), vitamin B5 (pantothenic acid, calcium pantothenate, d-panthenol or d-calcium pantothenate), vitamin B6 (pyridoxine, pyridoxal, pyridoxamine or pyridoxine hydrochloride), vitamin B12 (cobalamin or cyanocobalamin), folic acid, folate, folacin, vitamin H (biotin), vitamin C (ascorbic acid, sodium ascorbate, calcium ascorbate or ascorbyl palmitate), vitamin D (cholecalciferol, calciferol or ergocalciferol), vitamin E (d-alpha-tocopherol, d-beta-tocopherol, d-gamma-tocopherol, d-delta-tocopherol or d-alpha-tocopheryl acetate) and vitamin K (phyloquinone or phytonadione).

Other additives include minerals such as boron (sodium tetraborate decahydrate), calcium (calcium carbonate, calcium caseinate, calcium citrate, calcium gluconate, calcium lactate, calcium phosphate, dibasic calcium phosphate or tribasic calcium phosphate), chromium (GTF chromium from yeast, chromium acetate, chromium chloride, chromium trichloride and chromium picolinate) copper (copper gluconate or copper sulfate), fluorine (fluoride and calcium fluoride), iodine (potassium iodide), iron (ferrous fumarate, ferrous gluconate or ferrous sulfate), magnesium (magnesium carbonate, magnesium gluconate, magnesium hydroxide or magnesium oxide), manganese (manganese gluconate and manganese sulfate), molybdenum (sodium molybdate), phosphorus (dibasic calcium phosphate, sodium phosphate), potassium

(potassium aspartate, potassium citrate, potassium chloride or potassium gluconate), selenium (sodium selenite or selenium from yeast), silicon (sodium metasilicate), sodium (sodium chloride), strontium, vanadium (vanadium sulfate) and zinc (zinc acetate, 5 zinc citrate, zinc gluconate or zinc sulfate).

Other additives include amino acids, peptides, and related molecules such as alanine, arginine, asparagine, aspartic acid, carnitine, citrulline, cysteine, cystine, dimethylglycine, gamma-aminobutyric acid, glutamic acid, 10 glutamine, glutathione, glycine, histidine, isoleucine, leucine, lysine, methionine, ornithine, phenylalanine, proline, serine, taurine, threonine, tryptophan, tyrosine and valine.

Other additives include animal extracts such as cod liver oil, marine lipids, shark cartilage, oyster shell, bee 15 pollen and d-glucosamine sulfate.

Other additives include unsaturated free fatty acids such as γ -linoleic, arachidonic and α -linolenic acid, which may be in an ester (e.g. ethyl ester or triglyceride) form.

Other additives include herbs and plant extracts such 20 as kelp, pectin, Spirulina, fiber, lecithin, wheat germ oil, safflower seed oil, flax seed, evening primrose, borage oil, blackcurrant, pumpkin seed oil, grape extract, grape seed extract, bark extract, pine bark extract, French maritime pine bark extract, muira puama extract, fennel seed extract, dong 25 quai extract, chaste tree berry extract, alfalfa, saw palmetto berry extract, green tea extracts, angelica, catnip, cayenne, comfrey, garlic, ginger, ginseng, goldenseal, juniper berries, licorice, olive oil, parsley, peppermint, rosemary extract, valerian, white willow, yellow dock and yerba mate.

30 Other additives include enzymes such as amylase, protease, lipase and papain as well as miscellaneous substances such as menaquinone, choline (choline bitartrate), inositol, carotenoids (beta-carotene, alpha-carotene, zeaxanthin, cryptoxanthin or lutein), para-aminobenzoic acid, betaine HCl,

free omega-3 fatty acids and their esters, thiotic acid (alpha-lipoic acid), 1,2-dithiolane-3-pentanoic acid, 1,2-dithiolane-3-valeric acid, alkyl polyglycosides, polysorbate 80, sodium lauryl sulfate, flavanoids, flavanones, flavones, flavonols, 5 isoflavones, proanthocyanidins, oligomeric proanthocyanidins, vitamin A aldehyde, a mixture of the components of vitamin A₂, the D Vitamins (D₁, D₂, D₃ and D₄) which can be treated as a mixture, ascorbyl palmitate and vitamin K₂.

The nutritional supplement of the invention is 10 typically a viscous oil and can be added to a foodstuff composition during processing of the foodstuff. Such a foodstuff composition is often referred to as a functional food, and can be any food that will tolerate the physicochemical properties of the nutritional supplement, for example, 15 margarine, cooking oil, shortening or mayonnaise. It can also be packaged for consumption in softgel, capsule, tablet or liquid form. It can be supplied in edible polysaccharide gums, for example carrageenan, locust bean gum, guar, tragacanth, cellulose and carboxymethylcellulose.

20 The nutritional supplement can also be microencapsulated. Microencapsulation can be carried out, for example, using a gelatin such as bovine gelatin in a co-extrusion process, prior to processing into a foodstuff composition, for example baked goods, candy, margarines and 25 spreads, ice cream, yogurts, frozen desserts, cake mixes and pudding mixes. The packaging of the nutritional supplement should preferably provide physical protection from such effects as pH, particularly basic conditions, oxidation and degradation by light. This latter effect can be minimized for example by 30 changing the mesh size of the microencapsulation or inclusion of a suitable dye. The nutritional supplement can also be stored in a light-opaque container to minimize photodegradation.

The example below describes synthesis of an ester of the invention. Esterification can be performed according to

known methods, such as acid catalysis (US Patent No. 5,892,068: Higgins III, issued April 6, 1999). Preferably however, a base is used to promote esterification, more preferably transesterification. More preferably, the base is a metal (C₁-C₁₀)alkoxide, even more preferably sodium methoxide or ethoxide.

Examples

Synthesis of Stigmasterol/Omega-3 Fatty Acid Esters

10 A mixture of dry stigmasterol (3 g, 7.27 mmol) and a highly concentrated mixture of EPA and DHA omega-3 fatty acids in ethyl ester form (EPAXTM 5500, ProNova; 4.3 g, 12.6 mmol) were heated while being stirred magnetically at 140 to 145°C for 2 hours under vacuum (5 mm). Subsequently the vacuum was
15 disconnected and powdered sodium methoxide (40 mg, 0.75 mmol) was added quickly in one portion. The vacuum was connected immediately and the mixture was stirred at 140 to 145°C for an additional 4 hours. Hexane (25 mL) was added to precipitate the residual stigmasterol and the mixture was centrifuged for 5
20 minutes at 15,000 g (0°C), the supernatant was removed and the pellet was washed again with 5 mL of hexane. The remaining precipitate was centrifuged off and the supernatants combined. The organic phase was washed with water (5 mL), dried over sodium sulfate and the solvent removed under reduced pressure.
25 TLC (hexane/diethylether/acetic acid (90:10: 1), R_f 0.71. The yield was 5.9 g (85 %). The ester product was a viscous oil.

When the experiment was repeated using freshly made sodium ethoxide, almost the same level of conversion was obtained as with sodium methoxide. However, this was not seen
30 with commercially available sodium ethoxide, which performed more poorly than sodium methoxide.

References

- 1 Criqui, M.H. Triglycerides and cardiovascular disease: a focus on clinical trials. (1998) Eur Heart Journal 19 (Suppl A), A36-A39.
- 5 2 Grundy, S.M. Small LDL, atherogenic dyslipidemia, and the metabolic syndrome. (1997) Circulation 95, 1-4.
- 3 Grundy, S.M. Hypertriglyceridemia, atherogenic dyslipidemia, and the Metabolic Syndrome. (1998) Am J Cardiol 81, 18B-25B.
- 10 4 Gotto Jr., A.M. Triglyceride: the forgotten risk factor. (1998) Circulation 97, 1027-1028.
- 5 Jeppeson, J., Hein, O.H., Suadicani, P. and Gyntelberg, F. Triglyceride concentration and ischemic heart disease: an eight-year follow-up in the Copenhagen male study. (1998) Circulation 97, 1029-1036.
- 15 6 Franceschini, G. and Paoletti, R. Pharmacological control of hypertriglyceridemia. (1993) Cardiovasc Drugs Ther 7, 297-302.
- 7 Eisenberg, D. The importance of lowering cholesterol in patients with coronary heart disease. (1998) Clin Cardiol 21, 81-84.
- 20 8 Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). (1994) Lancet 344, 1383-1389.
- 25 9 Shepherd, J., Cobbe, S.M., Ford, I., Isles, C.G., Lorimer, A.R., MacFarlane, P.W., McKillop, J.H. and Packard, C.J. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. (1995) N Engl J Med 333, 1301-1307.
- 30 10 Sacks, F.M., Pfeffer, M.A., Moye, L.A., Rouleau, J.L., Rutherford, J.D., Cole, T.G., Brown, L., Warnica, J.W., Arnold, J.M.O., Wun, C., Davis, B.R. and Braunwald, E. The effect of pravastatin on coronary events after myocardial

infarction in patients with average cholesterol levels.

(1996) N Engl J Med 335, 1001-1009.

11 Heinemann, T., Kullak-Ublick, G.A., Pietruck, B. and
von Bergmann, K. Mechanisms of action of plant sterols on
inhibition of cholesterol absorption: comparison of
sitosterol and sitostanol. (1991) Eur J Clin Pharmacol 40
(Suppl 1), S59-S63.

12 Ling, W.H. and Jones, P.J.H. Dietary phytosterols: a
review of metabolism, benefits and side effects. (1995)
Life Sci 57, 195-206.

13 Jones, P.J.H., MacDougall, D.E., Ntanios, F. and
Vanstone, C.A. Dietary phytosterols as cholesterol-lowering
agents in humans. (1997) Can J Physiol Pharmacol 75, 217-
227.

14 Vanhanen, H.T., Blomqvist, S., Ehnholm, C., Hyvonen,
M., Jauhiainen, M., Torstila, I. and Miettinen, T.A. Serum
cholesterol, cholesterol precursors, and plant sterols in
hypercholesterolemic subjects with different apoE
phenotypes during dietary sitostanol ester treatment.
(1993) J Lipid Res , 1535-1544.

15 Heinemann, T., Leiss, O. and von Bergmann, K. Effect
of low-dose sitostanol on serum cholesterol in patients
with hypercholesterolemia. (1986) Atherosclerosis 61, 219-
223.

16 Miettinen, T.A. and Gylling, H. Regulation of
cholesterol metabolism by dietary plant sterols. (1999)
Curr Opin Lipidol 10, 9-14.

17 Vanhanen, H.T., Kajander, J., Lehtovirta, H. and
Miettinen, T.A. Serum levels, absorption efficiency, faecal
elimination and synthesis of cholesterol during increasing
doses of dietary sitostanol esters in hypercholesterolaemic
subjects. (1994) Clin Sci 1994 87, 61-67.

18 Leaf, A. and Weber, P.C. Cardiovascular effects of n-3
fatty acids. (1988) N Engl J Med 318, 549-557.

- 19 Mishkel, G.J. and Cairns, J.A. Cardiovascular effects of w-3 polyunsaturated fatty acids (fish oils). (1990) Bailliere's Clin Haematol 3, 625-649.
- 20 Kinsella, J.E., Lokesh, B. and Stone, R.A. Dietary n-3 polyunsaturated fatty acids and amelioration of cardiovascular disease: possible mechanisms. (1990) Am J Clin Nutr 52, 1-28.
- 21 Connor, S.L. and Connor, W.E. Are fish oils beneficial in the prevention and treatment of coronary artery disease? (1997) Am J Clin Nutr 66 (Suppl), 1020S-1031S.
- 22 Burr, M.L., Fehily, A.M., Gilbert, J.F., Rogers, S., Holliday, R.M., Sweetnam, P.M., Elwood, P.C. and Deadman, N.M. Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: diet and reinfarction trial. (1989) Lancet 30, 757-761.
- 23 von Schacky, C., Angerer, P., Kothny, W., Theisen, K. and Mudra, H. The effect of dietary omega-3 fatty acids on coronary atherosclerosis: A randomized, double-blind, placebo-controlled trial. (1999) Ann Intern Med 130, 554-562.
- 24 GISSI-Prevenzione Investigators. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. (1999) Lancet 354, 447-455.
- 25 Harris, W.S. Fish oils and plasma lipid and lipoprotein metabolism in humans: a critical review. (1989) J Lipid Res 30, 785-807.
- 26 Carey, M.C., Small, D.M. and Bliss, C.M. Lipid digestion and absorption. (1983) Annu Rev Physiol 45, 651-677.


CLAIMS:

1. A nutritional supplement comprising a sterol and an omega-3 fatty acid, or an ester thereof, for lowering cholesterol and triglyceride levels in the bloodstream of a subject.

2. The nutritional supplement according to claim 1, wherein the sterol and omega-3 fatty acid are together in the form of an ester.

3. The nutritional supplement according to claim 1, wherein the omega-3 fatty acid, that is present as such or as a component of an ester, has the formula:

15



wherein R^1 is a (C_3 - C_{40}) alkenyl group comprising at least one double bond.

20


4. The nutritional supplement according to claim 3, wherein R^1 has from 2 to 5 double bonds.

5. The nutritional supplement according to claim 2, wherein the omega-3 fatty acid is eicosapentaenoic acid 20:5 ω 3 (EPA).

6. The nutritional supplement according to claim 2, wherein the omega-3 fatty acid is docosahexaenoic acid 22:6 ω 3 (DHA).

7. The nutritional supplement according to claim 2, wherein the sterol is stigmasterol.

8. The nutritional supplement according to claim 2,
wherein the sterol is sitosterol.
9. The nutritional supplement according to claim 2,
5 wherein the sterol is fucosterol.
10. The nutritional supplement according to claim 2,
wherein the sterol is fucostanol.
- 10 11. The nutritional supplement according to claim 2,
wherein the sterol is β -sitostanol.
12. The nutritional supplement according to claim 1,
wherein the sterol is a phytosterol.
- 15 13. The nutritional supplement according to claim 1,
wherein the omega-3 fatty acid is derived from fish oil.
14. A method of lowering cholesterol and triglyceride
20 levels in the bloodstream of a subject, the method including the
step of administering an effective amount of a nutritional
supplement comprising a sterol and an omega-3 fatty acid, or an
ester thereof, to a subject.
- 25 15. The method according to claim 14, wherein the sterol
and omega-3 fatty acid are together in the form of an ester.
16. The method according to claim 15, wherein the omega-3
fatty acid, that is present as such or as a component of an
30 ester, has the formula:



wherein R¹ is a (C₃-C₄₀)alkenyl group comprising at least one double bond.

17. The method according to claim 16, wherein R¹ has from 2 to 5 double bonds.

18. The method according to claim 15, wherein the omega-3 fatty acid is eicosapentaenoic acid 20:5ω3 (EPA).

10 19. The method according to claim 15, wherein the omega-3 fatty acid is docosahexaenoic acid 22:6ω3 (DHA).

20. The method according to claim 15, wherein the sterol is stigmasterol.

15

21. The method according to claim 15, wherein the sterol is sitosterol.

22. The method according to claim 15, wherein the sterol
20 is fucosterol.

23. The method according to claim 15, wherein the sterol is fucostanol.

25 24. The method according to claim 15, wherein the sterol is β-sitostanol.

25. The method according to claim 15, wherein the sterol is a phytosterol.

30

26. The method according to claim 15, wherein the omega-3 fatty acid is derived from fish oil.

ABSTRACT

Triglycerides and cholesterol in the bloodstream are important factors in the development in the development of cardiovascular disease. The present invention discloses a nutritional supplement comprising a sterol and an omega-3 fatty acid, or an ester thereof, for lowering cholesterol and triglyceride levels in the bloodstream of a subject. Preferably, the sterol and omega-3 fatty acid are together in the form of an ester.

10

660630" 46355500

COMBINED DECLARATION AND POWER OF ATTORNEY

A NUTRITIONAL SUPPLEMENT FOR LOWERING SERUM TRIGLYCERIDE AND CHOLESTEROL LEVELS

(check one) ☒ is attached hereto.

as U.S. Application Serial No.

as PCT International Application No.

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information known to me which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, §§1.56(a) and (b), which state:

"(a) A patent by its very nature is affected with a public interest. The public interest is best served, and the most effective patent examination occurs when, at the time an application is being examined, the Office is aware of and evaluates the teachings of all information material to patentability. Each individual associated with the filing and prosecution of a patent application has a duty of candor and good faith in dealing with the Office, which includes a duty to disclose to the Office all information known to that individual to be material to patentability as defined in this section. The duty to disclose information exists with respect to each pending claim until the claim is cancelled or withdrawn from consideration, or the application becomes abandoned. Information material to the patentability that is cancelled or withdrawn from consideration need not be submitted if the information is not material to the patentability of any claim remaining under consideration in the application. There is no duty to submit information which is not material to the patentability of any existing claim. The duty to disclose all information known to be material to patentability is deemed to be satisfied if all information known to be material to patentability of any claim issued in a patent was cited by the Office or submitted to the Office in the manner prescribed by §§1.97(b)-(d) and 1.98. However, no patent will be granted on an application in connection with which fraud on the Office was practiced or attempted or the duty of disclosure was violated through bad faith or intentional misconduct. The Office encourages applicants to carefully examine:

- (1) prior art cited in search reports of a foreign patent office in a counterpart application,
- (2) the closest information over which individuals associated with the filing or prosecution of a patent application believe any pending claim patentably defines, to make sure that any material information contained therein is disclosed to the Office.

- (b) Under this section, information is material to patentability when it is not cumulative to information already of record or being made of record in the application, and
- (1) It establishes, by itself or in combination with other information, a prima facie case of unpatentability of a claim; or
 - (2) It refutes, or is inconsistent with, a position the applicant takes in:
 - (i) Opposing an argument of unpatentability relied on by the Office, or
 - (ii) Asserting an argument of patentability.

A prima facie case of unpatentability is established when the information compels a conclusion that a claim is unpatentable under the preponderance of evidence, burden-of-proof standard, giving each term in the claim its broadest reasonable construction consistent with the specification, and before any consideration is given to evidence which may be submitted in an attempt to establish a contrary conclusion of patentability."

I hereby claim foreign priority benefits under 35 United States Code, §119 and/or §365 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate filed by me or my assignee disclosing the subject matter claimed in this application and having a filing date (1) before that of the application on which priority is claimed, or (2) if no priority claimed, before the filing of this application:

PRIOR FOREIGN APPLICATION(S)

<u>Number</u>	<u>Country</u>	<u>Filing Date</u> (<u>Day/Month/Year</u>)	<u>Date First</u> <u>Laid-open or</u> <u>Published</u>	<u>Date Patented</u> <u>or Granted</u>	<u>Priority Claimed?</u>
---------------	----------------	---	--	---	--------------------------

I hereby claim the benefit under 35 United States Code, § 119(e) of any United States provisional application(s) listed below:

<u>Application Number</u>	<u>Filing Date</u>
---------------------------	--------------------

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, §1.56(a) which became available between the filing date of the prior application and the national or PCT international filing date of this application:

PRIOR U.S. OR PCT APPLICATION(S)

<u>Application No.</u>	<u>Filing Date</u> (<u>day/month/year</u>)	<u>Status</u> (<u>pending, abandoned, granted</u>)
------------------------	---	---

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that wilful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such wilful false statements may jeopardize the validity of the application or any patent issued thereon.

•

JAMES D. KOKONIS (Reg. No. 21178)
ALAN R. CAMPBELL (Reg. No. 26129)
A. DAVID MORROW (Reg. No. 28816)
JAMES MCGRAW (Reg. No. 28168)
JOHN BOCHNOVIC (Reg. No. 29229)
JOY D. MORROW (Reg. No. 30911)
DONALD F. PHENIX (Reg. No. 32528)
R. ALLAN BRETT (Reg. No. 40476)
PHILIP D. LAPIN (Reg. No. P-44443)
GRANT W. LYNDY (Reg. No. P-44484)
RICHARD L. WOOD (Reg. No. 22839)
ERIC C. COHEN (Reg. No. 27429)
GERALD S. SCHUR (Reg. No. 22053)
JAMES A. SCHEER (Reg. No. 29434)
KATHLEEN A. RHEINTGEN (Reg. No. 34044)
THOMAS W. TOLPIN (Reg. No. 26700)
MITCHELL J. WEINSTEIN (Reg. No. 37963)

HUGH O'GORMAN (Reg. No. 26140)
NICHOLAS H. FYFE (Reg. No. 26134)
ROBERT D. GOULD (Reg. No. 27523)
THOMAS R. KELLY (Reg. No. 29244)
MICHAEL E. WHEELER (Reg. No. 29246)
JOHN E. PAXTON (Reg. No. 32389)
TOKUO HIRAMA (Reg. No. 32551)
YWE J. LOOPER (Reg. No. 43758)
KOHJI SUZUKI (Reg. No. P-44467)
A. SIDNEY KATZ (Reg. No. 24003)
JEROLD B. SCHNAYER (Reg. No. 28903)
JOSEPH R. MARCUS (Reg. No. 25060)
GERALD T. SHEKLETON (Reg. No. 27466)
DANIEL R. CHERRY (Reg. No. 29054)
EDWARD P. GAMSON (Reg. No. 29381)
SHANNON L. NEBOLSKY (Reg. No. 41217)
CHARLES R. KRIKORIAN (Reg. No. 40687)

PLEASE SEND CORRESPONDENCE TO:

WELSH & KATZ, LTD.
120 South Riverside Plaza, 22nd Floor
Chicago, Illinois 60606
U.S.A.
Tel: (312) 655-1500
Fax: (312) 655-1501

Post Office Address: 6030 South Street, Halifax, Nova Scotia, B3H 1S7, Canada